Valuation: Abivax

Market Cap 8.85B 10.25B 8.32B 7.57B 14.22B 980B 14.46B 97.47B 38.11B 491B 38.48B 37.65B 1,631B P/E 2026 *
-29x
P/E 2027 * -34.1x
Enterprise Value 7.75B 8.97B 7.28B 6.62B 12.45B 858B 12.66B 85.33B 33.36B 430B 33.69B 32.96B 1,428B EV / Sales 2026 *
103x
EV / Sales 2027 * 95x
Free-Float
92.81%
Yield 2026 *
-
Yield 2027 * -
1 day-3.66%
1 week-9.99%
Current month-3.39%
1 month-13.48%
3 months-0.77%
6 months-3.30%
Current year-14.70%
1 week 102.7
Extreme 102.7
114.8
1 month 102.7
Extreme 102.7
123.4
Current year 60.45
Extreme 60.45
139
1 year 57.5
Extreme 57.5
139
3 years 4.51
Extreme 4.51
139
5 years 4.51
Extreme 4.51
139
10 years 3.87
Extreme 3.87
139
Manager TitleAgeSince
Chief Executive Officer 68 2023-05-04
Director of Finance/CFO 63 2017-01-01
Chief Tech/Sci/R&D Officer - 2023-09-30
Director TitleAgeSince
Chairman 66 2022-08-15
Chairman 68 2023-05-04
Director/Board Member 60 2023-07-10
Date Insider Type Main position Quantity % Market Cap.
7/15/26 Sell

Chairman

-3,375 0.0042%
7/11/26 Fiscal year

Chief Executive Officer

17,728 0.0222%
7/11/26 Fiscal year

Chairman

12,500 0.0157%
Change 5-day change 1-year change 3-year change Capi.($)
-3.66%-9.99%+74.07%+498.48% 10.25B
-1.78%-1.68%+1.99%+13.84% 48.42B
+0.85%-0.70%+465.55%+579.03% 43.66B
-2.40%-0.23%+12.20%+70.22% 39.51B
-2.01%-0.85%+24.95%+7.51% 38.95B
-0.50%+0.85%+20.60%+49.65% 32.61B
-0.59%-2.06%+26.13%+117.79% 16.15B
+0.38%-3.23% - - 16.32B
+0.49%+0.92%+4.32%+22.16% 14.16B
-0.43%+4.70%+79.75%+29.11% 13.37B
Average -0.96%-0.56%+78.84%+154.20% 27.34B
Weighted average by Cap. -1.02%+0.19%+96.70%+149.19%

Financials

2026 *2027 *
Net sales 74.92M 86.75M 70.4M 64.03M 120M 8.29B 122M 825M 323M 4.15B 326M 319M 13.8B 82.73M 95.79M 77.74M 70.7M 133M 9.16B 135M 911M 356M 4.59B 360M 352M 15.24B
Net income -265M -307M -249M -227M -426M -29.35B -433M -2.92B -1.14B -14.7B -1.15B -1.13B -48.85B -231M -267M -217M -197M -371M -25.55B -377M -2.54B -993M -12.79B -1B -981M -42.51B
Net Debt -1.1B -1.28B -1.04B -942M -1.77B -122B -1.8B -12.14B -4.75B -61.13B -4.79B -4.69B -203B -993M -1.15B -933M -848M -1.59B -110B -1.62B -10.93B -4.27B -55.03B -4.31B -4.22B -183B
Logo Abivax
Abivax is a clinical-stage biotechnology company focused on the development of therapeutics that exploit the body's natural regulatory mechanisms to stabilize the immune response in patients suffering from chronic inflammatory diseases. Based in France and the United States, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderate to severe active ulcerative colitis.
Employees
80
Date Price Change Volume
26-08-14 €102.70 -3.66% 102,656
26-08-13 €106.60 -2.47% 88,759
26-08-12 €109.30 -0.64% 85,347
26-08-11 €110.00 -0.99% 68,651
26-08-10 €111.10 -2.63% 78,187
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
102.70EUR
Average target price
138.56EUR
Spread / Average Target
+34.92%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABVX Stock